• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Adventrx Pharma Acquiring SynthRx

      Posted Atdrugdiscovery.pharmaceutical-business-review.com

      Adventrx Pharmaceuticals, a specialty pharmaceutical company engaged in acquiring, developing and commercializing proprietary product candidates, has taken over SynthRx, under a definitive merger agreement signed between the companies in February 2011.

      Following the acquisition, SynthRx's lead product candidate, poloxamer 188, a novel, proprietary, rheologic and antithrombotic compound, will be developed by Adventrx as ANX-188.

      Adventrx CEO Brian Culley said their plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication.

      April 15, 2011

       

      Share this Article!

    Back to top^